| Cat#: | INH-003 |
| Description/Features: | Same activities as rosaglitazone but different formulation. Antidiabetic, hypoglycemic agent. Potent and selective peroxisome proliferator-activated receptor γ (PPAR-γ) agonist. Potent insulin sensitizing agent binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. Ameliorates insulin resistance. Improves blood pressure and vascular function. Enhances proliferation of endogenous neural progenitor cells (NPCs). Anti-inflammatory compound. Has controversial therapeutic effects on the cardiovascular system. Promotes adipocyte differentiation of mesenchymal stem cells (MSCs). |
| Forms: | White to off-white powder. |
| Purity: | ≥98% (NMR) |
| Formula: | C18H19N3O3S . C4H4O4 |
| MW: | 357.4 . 116.1 |
| CAS: | 155141-29-0 |
| Solubility: | Soluble in ethanol or buffered aqueous solutions with pH 2.3. |
| Identity: | Determined by IR and 1H-NMR. |
| Synonyms: | BRL 49653C; Rosiglitazone XR; Avandia |
| Storage: | Stable for at least 2 years after receipt when stored at +4°C. Stock solutions are stable for at least 3 months when stored at -20°C. |
